{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-cell+Infusion&page=2", "query": { "intervention": "T-cell Infusion", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=T-cell+Infusion&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-22T06:31:17.521Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05686226", "title": "E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cervical Cancer", "Throat Cancer", "Oropharynx Cancer", "Anal Cancer", "Vulva Cancer", "Vaginal Cancer", "Penile Cancer", "Metastatic Cancer", "HPV-Related Malignancy", "HPV-Related Carcinoma", "HPV-Related Cervical Carcinoma", "HPV-Related Squamous Cell Carcinoma", "HPV-Related Adenocarcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Associated Vaginal Adenocarcinoma", "HPV-Related Adenosquamous Carcinoma", "HPV-Related Endocervical Adenocarcinoma", "HPV-Related Anal Squamous Cell Carcinoma", "HPV-Related Penile Squamous Cell Carcinoma", "HPV-Related Vulvar Squamous Cell Carcinoma", "HPV Positive Rectal Squamous Cell Carcinoma" ], "interventions": [ { "name": "E7 TCR-T cells", "type": "BIOLOGICAL" }, { "name": "Aldesleukin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Christian Hinrichs", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2023-03-07", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2026-06-12", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 3, "location_summary": "Bethesda, Maryland • New Brunswick, New Jersey", "locations": [ { "city": "Bethesda", "state": "Maryland" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05686226" }, { "nct_id": "NCT07192432", "title": "Gene Therapy for HER-Positive Cancer (SENTRY-HER2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HER2 Expressing Solid Tumors" ], "interventions": [ { "name": "Dose Level 1, VNX-202", "type": "GENETIC" }, { "name": "Dose Level 2, VNX-202", "type": "GENETIC" }, { "name": "Dose Level 3, VNX-202", "type": "GENETIC" }, { "name": "Dose Level 4, VNX-202", "type": "GENETIC" } ], "intervention_types": [ "GENETIC" ], "sponsor": "Vironexis Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2025-11-18", "completion_date": "2033-10", "has_results": false, "last_update_posted_date": "2026-07-28", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 11, "location_summary": "Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT07192432" }, { "nct_id": "NCT03361748", "title": "Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "bb2121", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2017-12-13", "completion_date": "2023-12-20", "has_results": true, "last_update_posted_date": "2025-05-23", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 18, "location_summary": "San Francisco, California • Atlanta, Georgia • Boston, Massachusetts + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03361748" }, { "nct_id": "NCT04648046", "title": "CAR-T Cells for HIV Infection", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "LVgp120duoCAR-T cells, low dose", "type": "BIOLOGICAL" }, { "name": "LVgp120duoCAR-T cells, high dose", "type": "BIOLOGICAL" }, { "name": "Analytic Treatment Interruption", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "Steven Deeks", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 18, "start_date": "2021-03-01", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-04-09", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 2, "location_summary": "Sacramento, California • San Francisco, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04648046" }, { "nct_id": "NCT06514794", "title": "A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "T-cell Acute Lymphoblastic Leukemia", "Lymphoblastic Lymphoma" ], "interventions": [ { "name": "WU-CART-007", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Allotera Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": null, "sex": "ALL", "summary": "6 Months and older" }, "enrollment_count": 125, "start_date": "2025-01-31", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 16, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 12 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06514794" }, { "nct_id": "NCT02397720", "title": "Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Diagnosed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Bilineal Leukemia", "Acute Biphenotypic Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Myeloid Leukemia", "Secondary Acute Myeloid Leukemia", "Therapy-Related Acute Myeloid Leukemia" ], "interventions": [ { "name": "Azacitidine", "type": "DRUG" }, { "name": "Ipilimumab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2015-04-07", "completion_date": "2023-10-09", "has_results": true, "last_update_posted_date": "2025-06-08", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02397720" }, { "nct_id": "NCT00996359", "title": "Partially HLA-Matched Irradiated Allogeneic Cellular Therapy After Reduced Intensity Total Body Irradiation", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Irradiated haploidentical allogeneic lymphocytes", "type": "BIOLOGICAL" }, { "name": "total-body irradiation", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Medicine and Dentistry of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 4, "start_date": "2009-10", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00996359" }, { "nct_id": "NCT06126341", "title": "A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "Lecture on the role of cellular therapies in relapse/refractory multiple myeloma/RRMM", "type": "OTHER" }, { "name": "Hospital Anxiety and Depression Scale", "type": "BEHAVIORAL" }, { "name": "Duke-UNC Functional Social Support Questionnaire", "type": "BEHAVIORAL" }, { "name": "Distress Thermometer", "type": "BEHAVIORAL" }, { "name": "FACT-BMT", "type": "BEHAVIORAL" }, { "name": "Psychosocial Assessments of Candidates for Transplantation", "type": "BEHAVIORAL" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 49, "start_date": "2023-11-03", "completion_date": "2029-05-03", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 8, "location_summary": "Hartford, Connecticut • Basking Ridge, New Jersey • Middletown, New Jersey + 5 more", "locations": [ { "city": "Hartford", "state": "Connecticut" }, { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06126341" }, { "nct_id": "NCT01029873", "title": "QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Melanoma" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "ALT-801", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2010-02", "completion_date": "2013-09", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 8, "location_summary": "Los Angeles, California • Orlando, Florida • Atlanta, Georgia + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01029873" }, { "nct_id": "NCT06665256", "title": "Phase 2 Study of Rapcabtagene Autoleucel in Myositis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Idiopathic Inflammatory Myopathies" ], "interventions": [ { "name": "Rapcabtagene autoleucel", "type": "BIOLOGICAL" }, { "name": "Active Comparator Option", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 21, "start_date": "2024-12-17", "completion_date": "2032-11-29", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-22T06:31:17.521Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Zephyrhills, Florida • Augusta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Zephyrhills", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06665256" } ] }